Bipolar disorder, formerly known as manic-depressive disorder, is a mental health disorder that can cause extreme mood swings, including high mood (mania or mild hypomania) and low mood (depression). Ace Therapeutics provides preclinical research and development services for bipolar disorder, helping clients accelerate the translation of novel therapies from the lab to the clinic. Our services include drug screening, design optimization, ex vivo and in vivo efficacy evaluation, safety testing, pharmacokinetic studies, and biomarker identification and validation. Our services are designed to provide pharmaceutical companies and research institutions with comprehensive, customized solutions to help clients achieve key breakthroughs in the early stages of bipolar disorder drug discovery and development, and to identify a solid foundation for more effective and safer therapeutic options.

Key Targets for Anti-Bipolar Disorder Drug Development

• Inhibition of neurotransmitter reuptake.
• Inhibit neurotransmitter degradation.
• Regulation of neurotransmitter release.
• Regulation of neurotransmitter activity.
• Modulation of signaling pathways.
• Regulation of neuronal excitability.
• Modulation of neuromodulatory systems in the brain.
• Regulation of neuroinflammatory response.

How Can We Help?

Pathophysiologic Mechanism Research Services of Bipolar Disorder

The pathophysiology of BD involves interactions between multiple genetic, neurochemical, and environmental factors. Ace Therapeutics combines animal models, cellular models, and our advanced technologies to help clients delve deeper into the genetic components, signaling pathways, biochemical changes, and neuroimaging findings associated with BD. Our services are designed to assist clients in gaining a deeper understanding of the disease's underlying pathophysiology and neurobiological mechanisms, thereby advancing the development of effective drugs.

Our experienced specialists can help you make progress in the following areas:

• Research of neurotransmitters associated with bipolar disorder. Such as norepinephrine, serotonin, dopamine, and gamma-aminobutyric acid.
• Research of the neuroendocrine system associated with bipolar disorder. Such as the hypothalamic-pituitary-adrenocortical axis, gonadal and thyroid hormones.
• Research of intracellular signaling involved in bipolar disorder. Such as changes in neuronal membranes, G proteins, Gs/cAMP signaling pathway, phosphatidylinositol pathway.
• Neuroplasticity studies related to bipolar disorder. Such as troponin E, brain-derived neurotrophic factor, GSK-3.
• Researches of circadian rhythm-related genes involved in bipolar disorder. Such as CLOCK, BMAL1, mPer1, mPer2, mPer3, mTim, mCry1 and mCry2.
• Researches of epigenetic mechanisms involved in bipolar disorder, including DNA methylation, translational repair following histone N-terminal acetylation or methylation, and transcriptional gene expression.
• Research of mechanisms related to mitochondrial dysfunction, oxidative stress, immuno-inflammatory imbalance and impaired hypothalamic-pituitary-adrenal axis leading to BD.
• Changes in brain regions, functional connectivity, and neuronal activity associated with BD are studied by neuroimaging and histopathology techniques.

Fig. 1 Integrated view of clinical and fundamental research interventions in bipolar disorder (BD). (Kim, Y.; et al., 2017)

Preclinical Screening and Evaluation Services for Anti-Bipolar Disorder Drugs

Ace Therapeutics provides preclinical development services for anti-bipolar disorder drugs. Our services can effectively improve the efficiency and success of drug studies and ultimately accelerate the process of bringing new drugs to market. Our services include the following areas

• Drug screening and quality assessment: We can select drugs with bipolar disorder therapeutic potential through in vitro screening and quality assessment.
• Pharmacodynamic studies: We can evaluate the therapeutic effects and mechanisms of action of drugs through animal models and in vitro experiments to provide a theoretical basis for subsequent clinical studies.
• Pharmacokinetic studies: We can evaluate the absorption, distribution, metabolism, and excretion characteristics of drugs in vivo to determine the optimal dose and dosing regimen.
• Safety assessment: We can assess the toxicity and risk of adverse reactions of drugs to organisms through toxicological studies.

Diagnostic Method Development Services for Bipolar Disorder

Ace Therapeutics is dedicated to assisting clients in the discovery and validation of BD-related neuroimaging biomarkers and peripheral blood biomarkers. Our objective is to facilitate the early identification and accurate diagnosis of the disease. Our comprehensive BD biomarker research services provide a solid scientific foundation for the development of in vitro diagnostic (IVD) and prompt oncology testing (POCT) products. They also help our clients advance in the field of precision medicine by promoting the innovation of bipolar disorder diagnostic technology.

Related Services

• Bipolar Disorder Animal Models
• Behavior Tests in Psychiatry
• Preclinical Imaging Services in Psychiatry
• Antipsychotics Screening Services
• Antipsychotic Discovery and Preclinical Services
• Pharmacokinetics Analysis Services for Antipsychotics

Ace Therapeutics has a professional and experienced R&D team that can provide the right solutions and solutions to ensure quality and efficiency in all aspects of the drug development process. We also have the relevant certifications and qualifications to ensure the legitimacy and compliance of the R&D process. If you are interested in our services, please contact us to learn how we can support you in your project.

References

1. Kim, Y.; et al. Molecular mechanisms of bipolar disorder: progress made and future challenges. Frontiers in cellular neuroscience. 11 (2017): 30.
2. Hu, X.; et al. Biomarkers and detection methods of bipolar disorder. Biosensors and Bioelectronics. 220 (2023): 114842.